MedTrace Logo

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

NCT06323239 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 148

Last updated 2026-05-11

No results posted yet for this study

Summary

This is a prospective, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of SBRT and LDRT combined with programmed death 1 (PD-1) antibody and chemotherapy in recurrent/metastatic nasopharyngeal carcinoma patients.

Conditions

  • Nasopharyngeal Carcinoma

Interventions

RADIATION

SBRT

SBRT for metastatic lesions

RADIATION

Low-dose Radiotherapy (LDRT)

LDRT for metastatic lesions

DRUG

Toripalimab

6 cycles for combined therapy. Toripalimab maintenance for 1 year.

DRUG

Gemcitabine

6 cycles for combined therapy.

DRUG

Cisplatin

6 cycles for combined therapy.

RADIATION

IMRT

IMRT for primary lesion

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Chong Zhao, MD. PhD. · Sun Yat-sen University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-15
Primary Completion
2026-12-31
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06323239 on ClinicalTrials.gov